Geneos Wealth Management’s Vir Biotechnology VIR Stock Holding History

Geneos Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60	Closed	-$604	–	2223
2023 Q4	$604	Hold	60	–	–	﹤0.01%	2075
2023 Q3	$562	Hold	60	–	–	﹤0.01%	2086
2023 Q2	$1.47K	Buy	+60	New	+$1.51K	﹤0.01%	1979
2023 Q1	–	Sell	-60	Closed	-$1.52K	–	2109
2022 Q4	$1.52K	Hold	60	–	–	﹤0.01%	1914
2022 Q3	$1K	Sell	60 -600	-91%	-$15.3K	﹤0.01%	1974
2022 Q2	$17K	Hold	660	–	–	﹤0.01%	1761
2022 Q1	$16K	Hold	660	–	–	﹤0.01%	1902
2021 Q4	$27K	Buy	660 +200	+43%	+$7.83K	﹤0.01%	1737
2021 Q3	$15K	Buy	+460	New	+$19.9K	﹤0.01%	2077
2020 Q4	–	Sell	-100	Closed	-$3K	–	3009
2020 Q3	$3K	Hold	100	–	–	﹤0.01%	2348
2020 Q2	$3K	Buy	+100	New	+$3.36K	﹤0.01%	2309

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geneos Wealth Management's VIR Position: Q1 2024 in Review

Geneos Wealth Management sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 60 shares — an estimated $604 sold.

Geneos Wealth Management first reported a position in VIR in Q2 2020 and held it in 11 quarters. The position peaked at $27K in Q4 2021. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

Geneos Wealth Management reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
Geneos Wealth Management sold 60 Vir Biotechnology shares in Q1 2024, an estimated $604.
Geneos Wealth Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 11 quarters.
Geneos Wealth Management's Vir Biotechnology position peaked at $27K in Q4 2021.
209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Geneos Wealth Management's 13F filing for Q1 2024, filed 3 May 2024.